Epidemiology and Antimicrobial Susceptibility of Salmonella enterica Bloodstream Isolates Among Febrile Children in a Rural District in Northeastern Tanzania: A Cross-sectional Study.
Anti-Bacterial Agents
/ pharmacology
Blood Culture
Child, Preschool
Community-Acquired Infections
/ blood
Cross-Sectional Studies
Drug Resistance, Multiple, Bacterial
Female
Fever
/ epidemiology
Humans
Infant
Infant, Newborn
Male
Microbial Sensitivity Tests
Rural Population
Salmonella Infections
/ blood
Salmonella enterica
/ drug effects
Tanzania
/ epidemiology
Salmonella Typhi
Epidemiology
antimicrobial resistance
non-typhoidal Salmonella
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
29
5
2020
Statut:
ppublish
Résumé
Salmonella enterica including Salmonella Typhi and nontyphoidal Salmonella (NTS) are the predominant cause of community-acquired bloodstream infections in sub-Saharan Africa (sSA). Multiple-drug resistance and emerging fluoroquinolone resistance are of concern. Data on the age distribution of typhoid fever in sSA are scarce but essential for typhoid conjugate vaccine policy. We sought to describe Salmonella bloodstream infections, antimicrobial resistance, and age distribution at a rural district hospital in northeastern Tanzania. From 2008 to 2016, febrile children or children with a history of fever aged 1 month to 5 years admitted to Korogwe District Hospital were enrolled. Demographic, clinical data and blood cultures were collected. Organisms were identified by conventional microbiological methods, and antimicrobial susceptibility test was done by disc diffusion. Of 4176 participants receiving blood cultures, 383 (9.2 %) yielded pathogens. Of pathogens, 171 (44.6%) were Salmonella enterica of which 129 (75.4%) were Salmonella Typhi, and 42 (24.6%) were NTS. The median (interquartile range age of participants was 13.1 (6.3-28.0) months for those with Salmonella Typhi and 11.5 (8.5-23.4) months for NTS. Of 129 Salmonella Typhi, 89 (89.9%) were resistant to amoxicillin, 85 (81.0%) to chloramphenicol, and 93 (92.1%) to trimethoprim-sulfamethoxazole compared with 22 (62.9%), 15 (39.4%), and 27 (79.4%), respectively, for NTS. Multidrug resistance was present in 68 (81.0%) of Salmonella Typhi and 12 (41.4%) of NTS. Salmonella Typhi was the leading cause of bloodstream infection among infants and young children <2 years of age admitted to Korogwe District Hospital. Multidrug resistance was common, highlighting a role for typhoid conjugate vaccine into routine infant vaccine schedules.
Sections du résumé
BACKGROUND
Salmonella enterica including Salmonella Typhi and nontyphoidal Salmonella (NTS) are the predominant cause of community-acquired bloodstream infections in sub-Saharan Africa (sSA). Multiple-drug resistance and emerging fluoroquinolone resistance are of concern. Data on the age distribution of typhoid fever in sSA are scarce but essential for typhoid conjugate vaccine policy. We sought to describe Salmonella bloodstream infections, antimicrobial resistance, and age distribution at a rural district hospital in northeastern Tanzania.
METHODS
From 2008 to 2016, febrile children or children with a history of fever aged 1 month to 5 years admitted to Korogwe District Hospital were enrolled. Demographic, clinical data and blood cultures were collected. Organisms were identified by conventional microbiological methods, and antimicrobial susceptibility test was done by disc diffusion.
RESULTS
Of 4176 participants receiving blood cultures, 383 (9.2 %) yielded pathogens. Of pathogens, 171 (44.6%) were Salmonella enterica of which 129 (75.4%) were Salmonella Typhi, and 42 (24.6%) were NTS. The median (interquartile range age of participants was 13.1 (6.3-28.0) months for those with Salmonella Typhi and 11.5 (8.5-23.4) months for NTS. Of 129 Salmonella Typhi, 89 (89.9%) were resistant to amoxicillin, 85 (81.0%) to chloramphenicol, and 93 (92.1%) to trimethoprim-sulfamethoxazole compared with 22 (62.9%), 15 (39.4%), and 27 (79.4%), respectively, for NTS. Multidrug resistance was present in 68 (81.0%) of Salmonella Typhi and 12 (41.4%) of NTS.
CONCLUSION
Salmonella Typhi was the leading cause of bloodstream infection among infants and young children <2 years of age admitted to Korogwe District Hospital. Multidrug resistance was common, highlighting a role for typhoid conjugate vaccine into routine infant vaccine schedules.
Identifiants
pubmed: 30845323
pii: 5371223
doi: 10.1093/cid/ciy1126
pmc: PMC6405276
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S177-S182Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
PLoS One. 2014 Aug 04;9(8):e104197
pubmed: 25090651
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
Lancet Glob Health. 2017 Mar;5(3):e310-e323
pubmed: 28193398
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Clin Infect Dis. 2012 Apr;54(8):1100-6
pubmed: 22357702
J Antimicrob Chemother. 2001 Jul;48 Suppl 1:43-57
pubmed: 11420336
PLoS One. 2018 Feb 12;13(2):e0192575
pubmed: 29432492
Emerg Infect Dis. 2010 Sep;16(9):1448-51
pubmed: 20735930
Vaccine. 2019 Jan 7;37(2):214-216
pubmed: 29661581
Trop Med Int Health. 2011 Jul;16(7):830-7
pubmed: 21470347
PLoS One. 2010 Feb 16;5(2):e9244
pubmed: 20168998
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S363-71
pubmed: 26449953
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Clin Infect Dis. 2012 Apr;54(8):1091-9
pubmed: 22357703
Clin Infect Dis. 2011 Feb 1;52(3):341-8
pubmed: 21217181
PLoS One. 2012;7(1):e29119
pubmed: 22276105
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Clin Infect Dis. 2014 Mar;58(5):638-47
pubmed: 24336909
Malar J. 2011 Oct 27;10:320
pubmed: 22029477
Vaccine. 2015 Jun 19;33 Suppl 3:C21-9
pubmed: 25912288
Clin Infect Dis. 2018 Nov 28;67(12):1824-1830
pubmed: 29746615
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
Malar J. 2017 Oct 27;16(1):433
pubmed: 29078773